Parse Biosciences and Codebreaker Labs launched a collaboration to combine engineered variant libraries with high‑throughput single‑cell transcriptomics to experimentally characterize how genetic variants alter cell states. The partnership aims to generate datasets that improve whole‑genome interpretation, aid target discovery and validate therapeutic hypotheses. Parse will apply its single‑cell platform to Codebreaker’s variant libraries to measure variant‑driven transcriptomic changes at scale. The data are intended to support drug discovery, AI model training and precision clinical trial design. The move follows Qiagen’s announced acquisition of Parse, which the companies said will further the reach of the resulting datasets. If successful, the platform could close gaps between variant annotation and functional evidence, addressing a bottleneck in genomic target validation and enabling more predictive preclinical pipelines.